Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 5Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

X-Rays 6Phantoms, Imaging 6Filgrastim 6Cyclophosphamide 6Carboplatin 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Ifosfamide 5Temozolomide 4Nuclear Medicine Department, Hospital 4Gemcitabine 4Etoposide 4Granulocyte Colony-Stimulating Factor 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ixabepilone 2ivosidenib 2etoposide phosphate 2ensartinib 2cabozantinib 2belinostat 2Vincristine 2Vemurafenib 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × cixutumumab × Genitourinary × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡